Rays
-
Seventy-five years have elapsed since its introduction and a renewed interest has arisen in the vaccination with bacillus Calmette-Guerin (BCG) for the prevention of tuberculosis. This interest has been motivated by the increase in tuberculosis, especially in multidrug-resistant tuberculosis. The efficacy of BCG has been questioned for decades, however, new epidemiological studies have shown a protective effect in some populations and categories at risk. ⋯ The use of this vaccination is advised for specific populations based on the risk of infection and disease. However, BCG has a limited benefit. New agents produced with methods of molecular biology are supplying encouraging results in the animal model.